TBPHTheravance Biopharma, Inc.

$700M

FY 2015 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+260.4% YoY

Gross Profit

$37M88.9% margin

Operating Income

-$182M-431.8% margin

Net Income

-$182M-432.6% margin

EPS (Diluted)

$-5.34

Cash Flow

Operating Cash Flow

-$169M

Free Cash Flow

-$172M

Stock-Based Comp.

$54M

Balance Sheet

Total Assets

$300M

Total Liabilities

$57M

Stockholders' Equity

$243M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$12M	+260.4%
Gross Profit	$37M	$8M	+391.1%
Operating Income	-$182M	-$233M	+21.8%
Net Income	-$182M	-$237M	+23.1%

TBPH FY 2015 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena